Evercore ISI raised the firm’s price target on Teladoc (TDOC) to $6 from $5 and keeps an In Line rating on the shares. The firm made several price target adjustments and additions to the firm’s Tactical call lists as part of the firm’s healthcare technology and distribution preview for Q1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Pineal Capital urges Teladoc to cut more costs, consider break-up of core units
- Teladoc Adds Susan Salka to Expanded Board of Directors
- Private Markets: OpenAI raises additional $10B funding
- Teladoc price target lowered to $7 from $8.50 at Barclays
- Buy/Sell: Wall Street’s top 10 stock calls this week